Sign inJoin waitlistJoin the waitlist

NS

Narek Shaverdian

Radiation Oncology Thoracic Disease Site Director · New York Presbyterian Hospital

Credentials: · · · ·

History

Thoracic Radiation Oncology · New York Presbyterian Hospital
Present

Radiation Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
2014–2018
University of Washington-Seattle Campus
2013–2014
University of Wisconsin School of Medicine and Public Health
2009–2013

Research

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
The Lancet Oncology · 2017 · First of 8 authors · 903 citations
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
JAMA Network Open · 2019 · 278 citations
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of…
The Lancet · 2024 · 251 citations

Daniel Gomez
55 papers
AR
Andreas Rimner
40 papers
DG
Daphna Gelblum
38 papers
AW
Abraham Wu
37 papers
Annemarie Shepherd
37 papers
CS
Charles Simone
35 papers
JC
Jamie Chaft
29 papers
Michael Steinberg
25 papers
Percy Lee
22 papers
MO
Michael Offin
16 papers · 4 as a fellow
Jacob Shin
11 papers
PI
Puneeth Iyengar
11 papers

Clinical trials

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2026–2028
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2029
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2026
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2026